For Q1 FY2026 (ended March 31, 2026), Eli Lilly reported revenue of $19.80 billion, up 55.5% year-over-year. Net income surged 168.1% to $7.40 billion, with diluted EPS of $8.26, up 169.9%. The company held $5.28 billion in cash, $31.20 billion in equity, and $39.37 billion in long-term debt.
•Revenue grew 55.5% YoY to $19.80 billion.
•Net income increased 168.1% to $7.40 billion.
•Diluted EPS rose 169.9% to $8.26.
•Long-term debt stood at $39.37 billion as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Eli Lilly and Company discovers develops, manufactures, and markets human pharmaceutical products globally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes.
Its portfolio also includes Jardiance, Mounjaro, and Trulicity for type 2 diabetes, and Zepbound for obesity oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma.
Its portfolio also includes Erbitux for colorectal cancers and head and neck cancers, Inluriyo for breast cancer, Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma, Retevmo for the treatment of metastatic NSCLC, TYVYT for classic hodgkin's lymphoma, and Verzenio for breast cancer.
Additionally, it offers immunology products, which include Ebglyss for severe atopic dermatitis. Its portfolio also includes Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19, Omvoh for ulcerative colitis, and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis
Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family. Its portfolio also includes F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab
License agreements with Almirall, S.A. for Ebglyss, Chugai Pharmaceutical Co., Ltd for orforglipron, strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases, and BioArctic AB (publ) for new treatment. Founded in 1876, Eli Lilly and Company is headquartered in Indianapolis, Indiana.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products globally. Its portfolio includes treatments for cardiometabolic health, such as Jardiance, Mounjaro, and Trulicity for type 2 diabetes, and Zepbound for obesity. In oncology, it offers Cyramza for gastric cancer, Verzenio for breast cancer, and Retevmo for metastatic NSCLC. Immunology products include Olumiant for rheumatoid arthritis and Taltz for plaque psoriasis. The company also provides Emgality for migraine prevention and Kisunla for symptomatic Alzheimer's disease. Eli Lilly collaborates with Boehringer Ingelheim on the Jardiance product family.
Where is Eli Lilly (LLY) listed and what currency does it trade in?
Eli Lilly and Company is listed on the New York Stock Exchange (NYSE) under the ticker symbol LLY. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and stock trading are conducted in USD, making it accessible to investors on major US exchanges.
What sector and industry does Eli Lilly (LLY) operate in?
Eli Lilly operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This classification encompasses companies that research, develop, and produce a wide range of pharmaceutical products for human use. As a drug manufacturer, Eli Lilly focuses on creating innovative therapies for chronic and acute conditions, including diabetes, cancer, autoimmune diseases, and neurological disorders.
What are some key products in Eli Lilly's (LLY) portfolio?
Eli Lilly's portfolio spans several therapeutic areas. In cardiometabolic health, key products include Jardiance (type 2 diabetes), Mounjaro (type 2 diabetes), Trulicity (type 2 diabetes), and Zepbound (obesity). Oncology offerings include Cyramza (gastric cancer), Verzenio (breast cancer), Retevmo (NSCLC), and Jaypirca (leukemia/lymphoma). Immunology products feature Olumiant (rheumatoid arthritis, atopic dermatitis, alopecia areata, COVID-19), Taltz (psoriasis, psoriatic arthritis), and Ebglyss (severe atopic dermatitis). Neurology products include Emgality (migraine prevention) and Kisunla (Alzheimer's disease).
Which countries or regions does Eli Lilly (LLY) serve?
Eli Lilly and Company operates globally, marketing its pharmaceutical products worldwide. While headquartered in the United States, the company has a significant international presence, with products distributed across multiple regions including Europe, Asia, and the Americas. Its collaborations, such as with Boehringer Ingelheim for the Jardiance product family, further extend its global reach. The company's diverse portfolio addresses health needs in both developed and emerging markets.